Results 211 to 220 of about 1,379,743 (300)

Clinicopathological and Immunohistochemical Correlation of Stromal CD10 Expression in Invasive Breast Carcinoma: A Prospective Observational Study. [PDF]

Iran J Pathol
P CK, Ramasamy J, Moorthi V, Prabhu, Kaliyamoorthy S, Radhakrishnan V.   +5 more
europepmc   +1 more source

CRISPR, APGAR and Cancer Screening: Public Engagement, Controversy and Misaligned Values

Bioethics, EarlyView.
ABSTRACT There are many calls for public engagement in decision‐making around controversial technologies, but far fewer calls for public engagement in deliberation around less controversial interventions. We think the public should be involved in discussing CRISPR, but not in discussing APGAR.
Stephen John
wiley   +1 more source

Utility of signal enhancement ratio on DCE-MRI for detection of residual breast cancer following surgery or neoadjuvant chemotherapy - a pilot study. [PDF]

Pol J Radiol
Johnson A, Sarawagi R, Malik R.
europepmc   +1 more source

Ductal Breast Carcinoma In Situ [PDF]

, 2020
openaire   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Male breast carcinoma in a 45-year-old without known risk factors: case report and literature review. [PDF]

Int J Surg Case Rep
Subedi S, Ghimire S, Regmi S, Sherchan R, Lakhanpal L.   +4 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Recent Advances in Pathogenesis, Diagnosis and Integrated Traditional Chinese Medicine Therapy for Plasma Cell Mastitis. [PDF]

Int J Gen Med
Kong X, Liu C, Zhang A, Wang K, Wang L, Chen H, Xu G.   +6 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source